Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1203-1208

  Li, Ping ^a,b,c   Callery, Patrick S ^b   Gan, Liang Shang ^a   Balani, Suresh K ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; AURANTIIN; BERGAMOTTIN; BERGAPTEN; CYTOCHROME P450 3A; ENALAPRIL; ESTERASE; FUROBENZOPYRAN DERIVATIVE; GALANGIN; HESPERIDIN; KAEMPFEROL; MEVINOLIN; MORIN; NARINGENIN; QUERCETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME INHIBITION; GRAPEFRUIT JUICE; HUMAN; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BEVERAGES; CACO-2 CELLS; CITRUS PARADISI; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENZYME INHIBITORS; ESTERASES; FLAVANONES; FLAVONOIDS; FOOD-DRUG INTERACTIONS; FRUIT; HUMANS; HYDROLYSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; KAEMPFEROLS; LOVASTATIN; MALE; MICROSOMES, LIVER; NITROPHENOLS; RATS; RATS, SPRAGUE-DAWLEY;

CITRUS X PARADISI; RATTUS; SUS;

EID: 34250704230     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013904     Document Type: Article

References (21)

1. Bailey DG, Arnold JM, Munoz C, and Spence JD (1993) Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 53:637-642.
2. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, and Bend JR (1998) Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′- dihydroxybergamottin in humans. Clin Pharmacol Ther 64:248-256.
3. Bailey DG, Spence JD, Edgar B, Bayliff CD, and Arnold JM (1989) Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 12:357-362.
4. Bailey DG, Spence JD, Munoz C, and Arnold JM (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268-269.
5. De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, and Derendorf H (2006) Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 54:249-255.
6. Edwards DJ, Bellevue FH 3rd, and Woster PM (1996) Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 24:1287-1290.
7. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, and Yamazoe Y (1997) Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396.
8. Guo LQ, Fukuda K, Ohta T, and Yamazoe Y (2000) Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A4 activity. Drug Metab Dispos 28:766-771.
9. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, and Duggan DE (1993) Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 21:1003-1011.
10. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, and Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259.
11. Ho PC, Saville DJ, Coville PF, and Wanwimolruk S (2000) Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharm Acta Helv 74:379-385.
12. Ho PC, Saville DJ, and Wanwimolruk S (2001) Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4:217-227.
13. Jignesh P, Balasubrahmanyam B, Surajit D, Mitra D, and Ashim K (2004) In vitro interaction of the HIV protease inhibitor Ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11:262-277.
14. Li P, Callery PS, Gan LS, and Balani SK (2007) Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos 35:1023-1031.
15. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, and George CF (1993) Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 36:460-463.
16. Ross SA, Ziska DS, Zhao K, and Elsohly MA (2000) Variance of common flavonoids by brand of grapefruit juice. Fitoterapia 71:154-161.
17. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, et al. (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228-1233.
18. van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, and Augustijns P (2002) Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 30:924-930.
19. Wadkins RM, Hyatt JL, Wei X, Yoon KJ, Wierdl M, Edwards CC, Morton CL, Obenauer JC, Damodaran K, Beroza P, et al. (2005) Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 48:2906-2915.
20. Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, Beroza P, Danks MK, and Potter PM (2004) Discovery of novel selective inhibitors of human intestinal carboxyl esterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 65:1336-1343.
21. Xia CQ, Liu N, Yang D, Miwa G, and Gan L-S (2005) Expression, localization and functional characterization of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33:637-643.